Genentech And CV Play Hardball | March 2, 2009 Issue - Vol. 87 Issue 9 | Chemical & Engineering News
Volume 87 Issue 9 | p. 23 | Concentrates
Issue Date: March 2, 2009

Genentech And CV Play Hardball

Department: Business

Genentech has told shareholders to reject Roche's $42 billion bid for the 44% of Genentech that Roche does not already own. Last month, Roche lowered its offer from $89.00 per share to $86.50, a price that Genentech says "substantially undervalues" the company. In a separate move, CV Therapeutics' board of directors has rejected a $1 billion takeover offer from the Japanese drug firm Astellas Pharma. CV says the price is too low and that it has its own plan to increase shareholder value.

 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society

Leave A Comment

*Required to comment